Veracyte, Inc.VCYT
What Veracyte, Inc. does.
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.
Through our leading portfolio of comprehensive molecular diagnostic tests, we are focused on progressing patient care from the current standard to a more individualized approach, leveraging each patient’s unique cancer biology to improve their outcomes. We serve global markets with two complementary models. In the United States, we offer laboratory developed tests, or LDTs, through our centralized Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified laboratories in South San Francisco and San Diego, California, supported by our cytopathology expertise in Austin, Texas. Outside of the United States, we provide in vitro diagnostic, or IVD, tests to patients through distribution to laboratories and hospitals that can perform the tests locally. In the United States, we currently offer tests in prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). Our international distribution of IVDs is currently focused on our Prosigna test and, in the future, we intend to offer Decipher Prostate as an IVD.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| Net income | -$34.9M | -$75.6M | -$36.6M | -$74.4M | $24.1M | $66.4M |
| Free cash flow | -$12.5M | -$37.0M | -$1.0M | $34.3M | $63.8M | $126.6M |
More on VCYT.
- Veracyte, Inc. summary
- Veracyte, Inc. financial statements
- Veracyte, Inc. key metrics
- Veracyte, Inc. health scores and style box
- Veracyte, Inc. earnings
- Veracyte, Inc. dividends
- Veracyte, Inc. valuation
- Veracyte, Inc. ownership and insiders
- Veracyte, Inc. peers
Figures from Veracyte, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.